Metastatic Malignant Solid Neoplasm Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +2 more
- Atezolizumab
- Laboratory Biomarker Analysis
- La Jolla, California
- +8 more
2022-04-06
Apr 6, 2022N
Recruiting
- Metastatic Malignant Solid Neoplasm
- Unresectable Solid Neoplasm
- Edodekin alfa
- Pembrolizumab
- La Jolla, California
- +27 more
2022-04-05
Apr 5, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +13 more
- Nivolumab
- Birmingham, Alabama
- +43 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Ann Arbor Stage III Lymphoma
- +4 more
- Copanlisib
- +2 more
- Bethesda, Maryland
- +2 more
2022-04-05
Apr 5, 2022N
Recruiting
- Metastatic Malignant Solid Neoplasm
- +3 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
- Cleveland, Ohio
- +1 more
2022-04-05
Apr 5, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Copanlisib Hydrochloride
- +2 more
- Boston, Massachusetts
- +5 more
2022-04-05
Apr 5, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +8 more
- Ipilimumab
- Nivolumab
- La Jolla, California
- +34 more
2022-04-05
Apr 5, 2022N
Recruiting
- Lymphoma
- +6 more
- Cytology Specimen Collection Procedure
- Birmingham, Alabama
- +139 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Breast Adenocarcinoma
- +9 more
- Entinostat
- +4 more
- Duarte, California
- +4 more
2022-04-05
Apr 5, 2022N
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +20 more
- Pembrolizumab
- Ziv-Aflibercept
- Tampa, Florida
- +8 more
2022-04-05
Apr 5, 2022N
Recruiting
- Advanced Breast Carcinoma
- +74 more
- Ceralasertib
- Trastuzumab Deruxtecan
- Los Angeles, California
- +9 more
2022-04-05
Apr 5, 2022N
Recruiting
- Advanced Differentiated Thyroid Gland Carcinoma
- +102 more
- Cabozantinib S-malate
- Nivolumab
- Chicago, Illinois
- +2 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Advanced Breast Carcinoma
- +25 more
- Docetaxel
- +3 more
- Aurora, Colorado
- +7 more
2022-04-02
Apr 2, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Copanlisib Hydrochloride
- +2 more
- Aurora, Colorado
- +7 more
2022-04-01
Apr 1, 2022N
Recruiting
- Advanced Breast Carcinoma
- +55 more
- Biopsy
- Talazoparib
- Bethesda, Maryland
- +1 more
2022-04-01
Apr 1, 2022N
Suspended
- Advanced Malignant Solid Neoplasm
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-03-31
Mar 31, 2022S
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +2 more
- Educational Intervention
- +3 more
- Fairbanks, Alaska
- +152 more
2022-03-29
Mar 29, 2022N
Recruiting
- Metastatic Colorectal Carcinoma
- +29 more
- Berzosertib
- Irinotecan Hydrochloride
- Los Angeles, California
- +22 more
2022-03-29
Mar 29, 2022N
Recruiting
- Locally Advanced Cholangiocarcinoma
- +28 more
- Avelumab
- +2 more
- Sacramento, California
- +6 more
2022-03-30
Mar 30, 2022N
Recruiting
- Metastatic Lung Small Cell Carcinoma
- +16 more
- Elimusertib
- +2 more
- Phoenix, Arizona
- +10 more
2022-03-25
Mar 25, 2022N
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- Dabrafenib Mesylate
- +2 more
- Los Angeles, California
- +15 more
2022-03-25
Mar 25, 2022M
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Laboratory Biomarker Analysis
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-03-24
Mar 24, 2022A
Recruiting
- CDK Gene Mutation
- +5 more
- Abemaciclib
- +2 more
- Anchorage, Alaska
- +385 more
2022-03-22
Mar 22, 2022N
Recruiting
- Advanced Malignant Solid Neoplasm
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- Binimetinib
- Houston, TexasUniversity of Texas MD Anderson Cancer Center LAO
2022-03-22
Mar 22, 2022N
Active, not recruiting
- COVID-19 Infection
- +3 more
- Biospecimen Collection
- +3 more
- Birmingham, Alabama
- +940 more
2022-03-19
Mar 19, 2022